Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison

被引：0
|
作者：
Zaheer, Hamza [1 ]
Zaheer, Muhammad Hammad [2 ]
机构：
[1] Serv Inst Med Sci, Lahore 54000, Punjab, Pakistan
[2] Allama Iqbal Med Coll, Lahore 54700, Punjab, Pakistan
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2024年 / 213卷
关键词：
D O I：
10.1016/j.diabres.2024.111759
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison
    Osumili, Beatrice
    Fan, Ludi
    Paik, Jim S.
    Pantalone, Kevin M.
    Ranta, Kari
    Sapin, Helene
    Tofe, Santiago
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 212
  • [2] Tirzepatide 5, 10, and 15 mg vs Injectable Semaglutide 0.5 mg for the Treatment of Type 2 Diabetes-An Indirect Treatment Comparison
    Pantalone, Kevin M.
    Tofe, Santiago
    Fan, Ludi
    Paik, Jim S.
    Ranta, Kari T.
    Sapin, Helene
    Osumili, Beatrice
    [J]. DIABETES, 2023, 72
  • [3] Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
    Vadher, Karan
    Patel, Hiren
    Mody, Reema
    Levine, Joshua A.
    Hoog, Meredith
    Cheng, Alice Y. Y.
    Pantalone, Kevin M.
    Sapin, Helene
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (09): : 1861 - 1868
  • [4] Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
    le Roux, Carel W.
    Hankosky, Emily R.
    Wang, Duzhe
    Malik, Raleigh
    Yu, Maria
    Hickey, Ana
    Kan, Hong
    Bunck, Mathijs C.
    Stefanski, Adam
    Garcia-Perez, Luis-Emilio
    Wharton, Sean
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (09): : 2626 - 2633
  • [5] Tirzepatide versus Semaglutide 2.4 mg for People with Obesity or Overweight and Type 2 Diabetes
    Hankosky, Emily
    Brumm, Julia Fraseur
    Malik, Raleigh
    Niemeyer, Anthony
    Wang, Fangyu
    Zhang, Xiaotian Michelle
    He, Xuanyao
    [J]. OBESITY, 2023, 31 : 83 - 84
  • [6] An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
    Pratley, Richard E.
    Catarig, Andrei-Mircea
    Lingvay, Ildiko
    Viljoen, Adie
    Paine, Abby
    Lawson, Jack
    Chubb, Barrie
    Gorst-Rasmussen, Anders
    Miresashvili, Nino
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (11): : 2513 - 2520
  • [7] Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States
    Mody, Reema
    Valentine, William J.
    Hoog, Meredith
    Sharland, Helen
    Belger, Mark
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (02): : 153 - 162
  • [8] Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
    Mody, Reema R.
    Meyer, Kellie L.
    Ward, Jennifer M.
    O'Day, Ken B.
    [J]. DIABETES THERAPY, 2023, 14 (12) : 2045 - 2055
  • [9] Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
    Reema R. Mody
    Kellie L. Meyer
    Jennifer M. Ward
    Ken B. O’Day
    [J]. Diabetes Therapy, 2023, 14 : 2045 - 2055
  • [10] Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis
    Yang, X. -Y.
    Yin, S.
    Yu, Y. -F.
    Hu, G.
    Hang, F. -Z.
    Zhou, M. -L.
    Liu, P.
    Jian, W. -X.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (15) : 7164 - 7179
12345